Rapid purification of a new humanized single-chain Fv antibody/human interleukin-2 fusion protein reactive against HER2 receptor

Acta Biochimica et Biophysica Sinica

Volumn 36, Issue 10, 2004, Pages 707-712

  Zhang, Wei Yun ^a   Yip, Tak Chun ^b   Kwok, Cheuk Sang ^c  

^a NANJING UNIVERSITY   (China)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Affinity chromatography; Fusion protein; Human embryonic kidney 293 cells; IL 2; Single chain Fv antibody

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ANTIGEN PURIFICATION; ARTICLE; CAPILLARY ELECTROPHORESIS; CELL CULTURE; CELL PROLIFERATION; CHEMOLUMINESCENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 10044241851     PISSN: 05829879     EISSN: None     Source Type: Journal    
DOI: 10.1093/abbs/36.10.707     Document Type: Article

References (18)

1. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res, 1991, 51: 944-948
2. Muller V, Thomssen C, Karakas C, Eustermann I, Ramirez Porras J, Coith C, Berger J et al. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers, 2003, 18(1): 13-20
3. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer, 2003, 89(5): 899-906
4. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R et al. HER2 expression in salivary gland carcinomas: Dependence on histological subtype. Clin Cancer Res, 2004, 10(3): 944-946
5. Korrapati V, Gaffney M, Larsson LG, Di Nunno L, Riggs M, Beissner RS, Rinehart JJ et al. Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clin Lung Cancer, 2001, 2(3): 216-219
6. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 1986, 232: 1644-1646
7. Cheng LS, Liu AP, Yang JH, Dong YQ, Li LW, Wang J, Wang CC et al. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2). Cell Res, 2003, 13(1): 35-48
8. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab and scientific update. Semin Oncol, 2001, 28(5Suppl16): 4-11
9. Zhang H, Wang Q, Montone KT, Peavey JE, Drebin JA, Greene MI, Murali R. Shared antigenic epitopes and pathobiological functions of anti-p185 (her2/neu) monoclonal antibodies. Exp Mol Pathol, 1999, 67(1): 15-25
10. Krastev Z, Koltchakov V, Tomov B, Koten JW. Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2. Hepatogastroenterology, 2003, 50(52): 1006-1016
11. Bukowski RM, McLain D, Olencki T, Budd GT, Murthy SA. Interleukin-2: Use in solid tumors. Stem Cells, 1993, 11(1): 26-32
12. Kobori G, Maegawa M, Ushida H, Maekawa S, Inoue K, Kaneko Y, Ohmori K et al. Two cases of renal cell carcinoma with ascites after interleukin-2 therapy. Hinyokika Kiyo, 2002, 48(7): 455-457
13. Baluna R, Vitetta ES. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology, 1997, 37(2-3): 117-132
14. Li J, Gyorffy SF, Ring DB, Kwok CS and Austin RC. Preparation and characterization of a recombinant humanized single-chain Fv antibody/human interleukin-2 fusion protein directed against the HER-2/neu (c-erb B2) proto-oncogene product, p185. Tumor Targeting, 1999, 4: 105-114
15. Kwok CS, Yip TC, Cheung WK, Leung KL, So FF, Ma WS, Lau WH. Preclinical study of a novel vasoactive human interleukin-2/single chain antibody fusion protein for HER-2 positive tumors. Proc AACR, 2003, 44: 1120 (Abstract 5625)
16. Baines D. Analysis of purity. In: Roe S ed. Protein Purification Techniques: A Practical Approach. Oxford: Oxford University Press, 2001, 36-37
17. Kilbourn RG, Fonseca GA, Trissel LA, Griffith OW. Strategies to reduce side effects of interleukin-2: Evaluation of the antihypotensive agent NG-monomethyl-L-arginine. Cancer J Sci Am, 2000, 6Suppl1: S21-830
18. Ettinghausen SE, Puri RK, Rosenberg SA. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst, 1988, 80(3): 177-188